Hui M B, Lien E J, Trousdale M D
Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California School of Medicine, Los Angeles 90033.
Antiviral Res. 1994 Aug;24(4):261-73. doi: 10.1016/0166-3542(94)90074-4.
Antiviral activities of four Schiff bases of aminohydroxyguanidine, designated ML1, ML4, ATL14 and LK11, were tested against human adenovirus types 5 and 8 (Ad5 and Ad8) in A549 cells by plaque reduction and virus yield reduction methods. Compound (ML1 1-(2'-hydroxy-5'-methoxybenzylidene)amino-3-hydroxyguanidine tosylate gave the best therapeutic indices (TC50/IC50) of 27.2 and 17.8 for Ad5 and Ad8, respectively. Pretreatment of cells with ML1 did not affect the adsorption nor the penetration of virus. Ultrastructure studies showed that only the drug treated infected cells had unidentified irregular shaped electron dense structures that might be drug altered viral macromolecules that were not assembled into complete infectious virus particles. Since these compounds have metal chelating properties, their antiviral activity may involve the early IA (EIA) gene which encodes a viral protein of 289 amino acid which has a zinc finger moiety that is required for its transactivation activity.
通过蚀斑减少法和病毒产量减少法,在A549细胞中测试了四种氨基羟基胍席夫碱(分别命名为ML1、ML4、ATL14和LK11)对5型和8型人腺病毒(Ad5和Ad8)的抗病毒活性。化合物ML1(1-(2'-羟基-5'-甲氧基亚苄基)氨基-3-羟基胍甲苯磺酸盐)对Ad5和Ad8的治疗指数(TC50/IC50)最佳,分别为27.2和17.8。用ML1预处理细胞不影响病毒的吸附和穿透。超微结构研究表明,只有经药物处理的受感染细胞具有形状不明的不规则电子致密结构,这些结构可能是药物改变的病毒大分子,未组装成完整的感染性病毒颗粒。由于这些化合物具有金属螯合特性,它们的抗病毒活性可能涉及早期IA(EIA)基因,该基因编码一种含289个氨基酸的病毒蛋白,其反式激活活性需要锌指部分。